Table 3: Non-susceptibilities of Pseudomonas aeruginosa of different studies.

Authors

Period

Samples

Population

Settings

MDR

XDR

PDR

Colistin NS

Amikacin NS

Ceftazidime
NS

Cefepime NS

Meropenem
NS

Piper/Tazo

NS

Ciprofloxacin NS

Shortridge D, et al. [2]

1997-2016

52022

All

≥ 400 medical centers representing the Asia-Pacific, European, Latin American, and North American regions

24.9

17.6

0.1

0.6%

7.0%

22.5

20.7

23.9

26.9

27.1

2013-2016

16461

21.8

15.2

0.1

 

 

19.2

 

22.6

 

 

BiedenbachDJ, et al. [7]

2012-2014

529

hospital-acquired or ventilator-associated pneumonia

5 medical centers in Vietnam

-

-

-

-

18.4

57.7

39.9

43.5

43.9

45.0

Phu VD, et al. [8]

2012-2013

100

Hospital-acquired infections

15 ICU in 14 hospital in Vietnam

-

-

-

-

-

-

-

55.7%*

-

-

Pfaller MA, et al. [9]

2013-2015

489

All hospitalized patients

14 medical centers located in 7 countries in the APAC region (minus China, Australia and New Zealand)

27.4

-

-

1.6%

7.8%

25.8%

20.9%

28.3%

27.9%

26.0%#

108

 

Korean

 

 

 

 

 

38.9%

 

46.3%

42.6%

 

37

 

India

 

 

 

 

 

32.4%

 

33.3%

40.5%

 

138

 

Thailand

 

 

 

 

 

27.5%

 

33.3%

29.0%

 

63

 

Singapore

 

 

 

 

 

20.6

 

17.5

19.0%

 

21

 

Taiwan

 

 

 

 

 

19.0%

 

19.0

25.0%

 

90

 

Malaysia

 

 

 

 

 

14.4

 

11.1

14.4

 

32

 

Hong Kong

 

 

 

 

 

12.5

 

15.6

15.6

 

Sader HS, et al. [10]

2012-2015

7452

All

79 U.S. medical centers

15.5

9.4

-

0.7

3.0

15.7

14.6

18.0

19.4

22.5

Our study

2019

244

All

A hospital in Vietnam

7.1

20.5

0.0

0.0

21.1

30.8

30.9

32.0

29.1

36.0

*Carbapenem resistance; #Levofloxaci